Phaseline

Targets › CD276

CD276 (CD276 antigen): drug programs, companies and trials

13 programs from 12 companies in 35 trials: 23 Phase 1, 8 Phase 2, 4 Phase 3; Oncology; next expected readout Dec 2026.

May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. (UniProt, Q5ZPR3)

Open in Phaseline: the race on CD276, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hansoh BioMedical R&D CompanyHS-20093
anti-B7-H3 antibody-drug conjugate
B7H3, CD276Phase 3Osteosarcoma; Small Cell Lung Cancer; Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma …Dec 2026
GSKRisvutatug Rezetecan (GSK5764227)
anti-B7-H3 antibody-drug conjugate
TROP2, CD276Phase 3Neoplasms, Lung; Neoplasms, Prostate; Neoplasms; Gastrointestinal NeoplasmsAug 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnoblituzumab
CD276 antigen cross-linking agent
CD276Phase 2Prostate CancerJul 2027
Pediatric Brain Tumor Consortium131I-Omburtamab
Radiolabeled anti-B7-H3 (CD276) monoclonal antibody for targeted radioimmunotherapy
CD276Phase 2Recurrent MedulloblastomaSep 2027
University Health Network, TorontoGSK5764227
Anti-B7-H3 antibody-drug conjugate
CD276Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJun 2030
Beijing Tiantan HospitalTX103-CAR-T Cell Injection
anti-B7-H3 CAR-T cell therapy
CD276Phase 1GlioblastomaDec 2026
Beijing BiotechEB-G3B7-NK dual-target CAR-NK cells
Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr
CD276, MSLN, EGFR, ERBB2, IL13RA2Phase 1Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) …Feb 2027
Beijing BiotechEB-DTNB-NK
Dual-target GD2/B7-H3 CAR-NK cells with IL-15 support and inducible safety switch
GYPC, CD276Phase 1Relapsed NeuroblastomaMar 2027
German Cancer Research CenterCC-3
Bispecific CD276xCD3 antibody
CD276, CD3EPhase 1Colorectal CancerMar 2027
National Cancer Institute (NCI)Autologous B7-H3 CAR T
anti-B7-H3 chimeric antigen receptor T cell therapy
CD276Phase 1Recurrent Small Cell Lung CancerJan 2030
UNC Lineberger Comprehensive Cancer CenterCAR.B7-H3T cells
Anti-B7-H3 CAR-T cells
CD276Phase 1Glioblastoma MultiformeMay 2030
Myricx PharmaMX006
Anti-B7-H3 antibody-drug conjugate
CD276Phase 1Advanced and/or Metastatic Solid Tumors Known to Express B7-H3Jul 2030
Innolake BiopharmILB-3101
B7-H3-targeting antibody-drug conjugate
CD276Phase 1Advanced Solid Tumor–

Conditions

Advanced Solid Tumor (3) Non-Small Cell Lung Cancer (3) Osteosarcoma (2) Glioblastoma (2) Neoplasms, Lung (2) Neoplasms (2) Prostate Cancer (2) Small Cell Lung Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Advanced Solid Tumors (1) Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (1) Metastatic Colorectal Cancer (CRC) (1)

Modalities

mixed (5), antibody (3), other (2), small molecule (2), protein or peptide (1)

Companies

Beijing Biotech (2) Hansoh BioMedical R&D Company (1) Beijing Tiantan Hospital (1) Pediatric Brain Tumor Consortium (1) Innolake Biopharm (1) Myricx Pharma (1) University Health Network, Toronto (1) GSK (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) German Cancer Research Center (1) UNC Lineberger Comprehensive Cancer Center (1) National Cancer Institute (NCI) (1)

Related targets

B7H3 (1) TROP2 (1) CD3E (1) MSLN (1) EGFR (1) ERBB2 (1) IL13RA2 (1) GYPC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.